Abstract
Over a decade has passed since the World Health Organization (WHO) proposed a set of "best buys" for the prevention of non-communicable diseases (NCDs). Loffreda and colleagues' review describes how, despite the cost-effectiveness of these interventions, their adoption is often complex and governments face many challenges in both implementing and maintaining NCD prevention policies. Industry opposition and the commercial determinants of health (CDoH) remain significant challenges to an effective NCD response. In addition, the best buys may operate inequitably and are often unable to respond to the interrelated challenges posed by the global syndemic of obesity. We suggest that the next revision of the best buys adopts a more integrated approach that prioritize structural interventions, equity-focused strategies, and mechanisms to counteract industry interference.